Publication | Closed Access
Sero‐epidemiological investigations on human herpesvirus 6 (HHV‐6) infections using a newly developed early antigen assay
47
Citations
29
References
1991
Year
HistocompatibilityViral DiagnosticsViral PathogenesisImmunologyPathologyEarly ProteinImmunotherapyEarly Antigen AssaySerologic TestingAntibody EngineeringLate ProteinHerpes Simplex Virus VaccinesDiagnostic VirologyAutoimmune DiseaseNeurovirologyVirologyAntibody ScreeningEpidemiologyHerpesvirusesHla TypingHuman Herpesvirus 6Sero‐epidemiological InvestigationsMonoclonal AntibodiesMedicine
Monoclonal antibodies (MAbs) were developed against immunodominant HHV-6 (GS isolate) late and early proteins. The major late protein was identified as a probable glycoprotein with a molecular weight of approximately 110 kDa (gp 110). Immunoblotting of the early antigen yielded proteins of 41 and 38 kDa (p41/38). The MAb to the early protein reacted with cells infected with 14 different HHV-6 isolates. In contrast, the MAb against the late protein reacted with only 10 of these isolates, indicating that there was strain variation in this glycoprotein. The percentage of antibody-positive sera reactive with gp110 in the ELISA ranged from 56% to 96% among the different serum donor categories. In contrast, only 10-30% of the sera were positive for antibodies to p41/38 with the exception of sera from patients with African Burkitt's lymphoma (ABL) and Hodgkin's disease (HD). These antibody patterns denote the presence of active HHV-6 replication in patients with ABL and HD.
| Year | Citations | |
|---|---|---|
Page 1
Page 1